Work

Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Year: 2022

Type: erratum

Source: Alzheimer s Research & Therapy

DOI: 10.1186/s13195-022-00995-9

Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer, Jeffrey L. Cummings

Institutions: Eisai (United States), Eisai (United Kingdom), Uppsala University, Berry Consultants, LLC (United States), University of Nevada, Las Vegas

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,590

OpenAlex ID: W4281250634

Cites: 1

Cited by: 19

Related to: 10